Amphastar Pharmaceuticals, Inc. Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
Amphastar Pharmaceuticals, Inc. (AMPH) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $1.68 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2026-02-26
- Amphastar Pharmaceuticals, Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $1.68M, a 18.53% increase from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $1.41M, a 42.89% decline from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $2.48M, a 392.25% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $503.00K, a 4472.73% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month |
|---|---|
| 2025-12-31 | $1.68M 10-K · filed 2026-02-26 |
| 2024-12-31 | $1.41M 10-K · filed 2026-02-26 |
| 2023-12-31 | $2.48M 10-K · filed 2026-02-26 |
| 2022-12-31 | $503.00K 10-K · filed 2025-03-03 |
| 2021-12-31 | $11.00K 10-K · filed 2024-02-29 |
| 2020-12-31 | $93.00K 10-K · filed 2023-03-01 |
| 2018-12-31 | $56.00K 10-K · filed 2021-03-15 |
| 2017-12-31 | $548.00K 10-K · filed 2020-03-16 |
| 2014-12-31 | $58.00K 10-K · filed 2017-03-15 |
| 2013-12-31 | $19.00K 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |